Skip to content

Evaluation of oral calcium effect in prevention OHSS (ovarian hyperstimulation syndrome) in high-risk patients

Evaluation of oral calcium effect versus placebo in the prevention of moderate to severe OHSS (ovarian hyperstimulation syndrome) in the high-risk patients for OHSS

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170417033490N2
Enrollment
150
Registered
2018-12-05
Start date
2017-09-12
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OHSS(ovarian hyperstimulation syndrome). Female infertility associated with anovulation

Interventions

Intervention 1: Intervention group: Patients with moderate to severe Ovarian Hyperstimulation Syndrome (OHSS) that received Calcium Carbonate 500mg orally every 12 hours for 5 days after injection of

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
16 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1- Antagonist protocol for Assisted reproductive technology (ART) 2- ) 2- The number of follicles = 20 mm is over 20. 3- The plasma estradiol level = 2500pg/ml

Exclusion criteria

Exclusion criteria: 1-patients with the endocrine disease as Diabetes mellitus, hyperprolactinemia, Cushing disease, congenital adrenal hyperplasia 2- Patients with the systemic disease as asthma, collagen vascular disease, hypercholesterolemia, cycle cell anemia 3- History of neoplasm 4-The plasma estradiol level is high (over 6000pg/ml). 5- Use of insulin-sensitization drugs 6- Patients that were required to the need to cycle cancellation.

Design outcomes

Primary

MeasureTime frame
Prevention of ovarian hyper stimulation syndrome. Timepoint: 7 to 14 days after administration of drug. Method of measurement: physical exam, transvaginal sonography and blood exam.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Dehbashi

Tehran University of Medical Sciences

zddoctor1390@gmail.com+98 21 4216 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026